Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-18T05:45:28.250Z Has data issue: false hasContentIssue false

A Comparative Study of Oxypertine and Trifluoperazine in Chronic Schizophrenia—A New Application of the Wing Rating Scale

Published online by Cambridge University Press:  29 January 2018

W. P. K. Calwell
Affiliation:
The Tavistock Clinic, London, W.I
M. Jacobsen
Affiliation:
Clinical Evaluation Unit, The Bayer Products Company, Surbiton, Surrey
A. Skarbek
Affiliation:
Psycholinguistic Research Unit, University College, London, W.C.1

Extract

A new series of compounds thought to have some of the properties of major tranquillizers has recently been synthesized (Archer et al., 1962). One of these, oxypertine (Fig. 1) has been made available to us under its code name, WIN.18, 501. Pharmacological studies have shown oxypertine to have tranquillizing, anti-adrenergic and hypotensive properties (Wylie and Archer, 1962).

Type
Research Article
Copyright
Copyright © Royal College of Psychiatrists, 1964 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Archer, S., Wyleb, D. W., Harris, L. S., Lewis, T. R., SCHULENBERG, J. W., BELL, M. R., KULLNIG, R. K., and Arnold, A. (1962). “i-(Indolylalkyl)-4-aryl-piperazines: a new class of tranquillisers.” J. Amer. chem. Soc., 84, 1306.Google Scholar
Durell, J., and Pollin, W. (1963). “A trial on chronic schizophrenic patients of oxypertine, a psychotropic drug with an indole ring.” Brit. J. Psychiat., 109, 687–91.Google Scholar
Foulds, G. A. (1958). “Clinical research in psychiatry.” J. Meni. Sci., 104, 259–65.Google Scholar
Gwynne, P. H., Hundziak, M., Kavtschitsch, J., Lefton, M., and Pasamanick, B. (1962). “Efficacy of trifluoperazine on withdrawal in chronic schizophrenia.” J. new. ment. Dis., 134, 451–55.Google Scholar
Heaton-Ward, W. A. (1962). “Inference and suggestion in a clinical trial (Niamid in mongolism).” J. Ment. Sci., 108, 865–70.Google Scholar
Oybir, F. (1962). “Trifluoperazine in chronic withdrawn schizophrenics (a double-blind study).” Dis. nerv. syst., 23, 348–50.Google Scholar
Rogers, N. R. (1963). “Trifluoperazine as a ‘mobilizing agent’ in chronic withdrawn schizophrenics.” Ibid., 24, 162–66.Google Scholar
Sterling-Winthrop Research Institute (1961). A revised summary of experimental laboratory and preliminary clinical tolerance data on WIN. 18, 501–2. New York.Google Scholar
WING, J. K. (1961). “A simple and reliable sub-classification of chronic schizophrenia.” J. Ment. Sci., 107, 862–75.Google Scholar
WING, J. K. and Brown, G. W. (1961). “Social treatment of chronic schizophrenia: a comparative study of three mental hospitals.” Ibid., 107, 847–61.Google Scholar
Wing, J. K., and Freudenberg, R. K. (1961). “The response of severely ill chronic schizophrenic patients to social stimulation.” Amer. J. Psychiat., 118, 311–22.Google Scholar
Wylie, D. W., and Archer, S. (1962). “Structure-activity relationships of i-[(3-indolyl)alkyl]-4-aryl-piperazines, a new series of tranquillisers.” J. med. pharm. Chem., 5, 932–43.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.